Format

Send to

Choose Destination
Clin Pharmacol Ther. 2013 Jun;93(6):539-46. doi: 10.1038/clpt.2013.24. Epub 2013 Feb 11.

Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system.

Author information

1
Stanford Center for Biomedical Informatics Research, Stanford University, Stanford, California, USA. rharpaz@stanford.edu

Abstract

Signal-detection algorithms (SDAs) are recognized as vital tools in pharmacovigilance. However, their performance characteristics are generally unknown. By leveraging a unique gold standard recently made public by the Observational Medical Outcomes Partnership (OMOP) and by conducting a unique systematic evaluation, we provide new insights into the diagnostic potential and characteristics of SDAs that are routinely applied to the US Food and Drug Administration (FDA) Adverse Event Reporting System (AERS). We find that SDAs can attain reasonable predictive accuracy in signaling adverse events. Two performance classes emerge, indicating that the class of approaches that address confounding and masking effects benefits safety surveillance. Our study shows that not all events are equally detectable, suggesting that specific events might be monitored more effectively using other data sources. We provide performance guidelines for several operating scenarios to inform the trade-off between sensitivity and specificity for specific use cases. We also propose an approach and demonstrate its application in identifying optimal signaling thresholds, given specific misclassification tolerances.

PMID:
23571771
PMCID:
PMC3857139
DOI:
10.1038/clpt.2013.24
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center